Connect with us

Published

on

Cells that make up the cartilage at the end of children’s and teens’ bones determine their future length and shape, which, in turn, affect height.  (Image credit: Marko Geber via Getty Images)

Scientists have pinpointed 145 potential “height genes” in cells that make up the cartilage at the ends of children’s bones and affect how tall they grow.

These cartilage cells, known as chondrocytes, multiply and mature in areas of tissue called growth plates, which sit near the ends of long bones in children and teens and determine each bone’s future length and shape. When a person’s growth is complete, these cartilaginous growth plates “close” and are replaced by hard bone. Scientists already knew that chondrocytes play a role in bone growth and human height, but narrowing down which genes control the cells’ growth — and, thus, our statures — has proved difficult.

“Pinpointing specific genes associated with human height is a challenging task, as height is a complex trait that is influenced by both genetic and environmental factors,” Dr. Nora Renthal (opens in new tab) , a pediatric endocrinologist at Boston Children’s Hospital and Harvard Medical School and senior of the new study, told Live Science in an email. “Our study focused on cartilage cells specifically because they are the primary cell type involved in bone growth.”

In a study published Friday (April 14) in the journal Cell Genomics (opens in new tab) , Renthal and her colleagues screened 600 million mouse cartilage cells to find genes that influence how the cells proliferate and mature. They used CRISPR genome-editing technology to “knock out” candidate genes, which allowed the researchers to observe what happened when these genes were erased and no longer regulated cartilage cells.

Related: What determines a person’s height? 

The researchers found 145 genes that, when knocked out, triggered abnormal growth and development of mouse cartilage cells. These patterns of abnormal growth were similar to those seen in certain skeletal disorders, such as skeletal dysplasia — a group of genetic disorders that affect the development of bones, joints and cartilage in babies. Those with skeletal dysplasia are typically of short stature and have short limbs, among other symptoms.

Next, the researchers compared these 145 mouse genes with previous results from large-scale genetic studies of human height, called genome-wide association studies (GWAS). In those studies, researchers compared the DNA of thousands of people of different heights to look for gene variants associated with height, Renthal explained. To control for non-genetic factors that influence the trait under study, such as nutrition and disease in the case of human height, these factors are incorporated into GWAS, according to a 2021 review published in the journal Nature Reviews Methods Primers (opens in new tab) .

“These studies have contributed to our understanding of the genetic basis of complex traits like height by identifying specific genetic regions and genes that are associated with the trait,” Renthal said.

The comparison revealed a remarkable overlap between genetic “hotpots” linked to human height in the GWAS and the 145 genes that control cartilage cell growth in mice. This means that these genes, which the researchers have now precisely located in the human genome, could influence height more than other genetic factors do.RELATED STORIES—More than 150 ‘made-from-scratch’ genes are in the human genome. 2 are totally unique to us.

—DeepMind’s AI used to develop tiny ‘syringe’ for injecting gene therapy and tumor-killing drugs

—Humans’ big-brain genes may have come from ‘junk DNA’ 

“Our current study has helped to identify new genes potentially involved in bone growth and development,” Renthal said. “Specific genes and pathways involved in the maturation and proliferation of chondrocytes, the cells that make up cartilage in our bones, play a critical role in human height.”

Results from mouse cells may not mirror cellular processes in humans, Renthal noted in a statement (opens in new tab) , but the researchers think height genes could come in handy in clinical settings. 

“It is our hope that the identification of these 145 genes will help patients with skeletal dysplasia and other skeletal disorders,” Renthal told Live Science.

Continue Reading

Technology

Palo Alto Networks reports earnings beat, says founder Nir Zuk retiring from company

Published

on

By

Palo Alto Networks reports earnings beat, says founder Nir Zuk retiring from company

Nikesh Arora, CEO of Palo Alto Networks, looks on during the closing bell at the Nasdaq Market in New York City on March 25, 2025.

Jeenah Moon | Reuters

Palo Alto Networks reported better-than-expected quarterly results and issued upbeat guidance for the current period. The cybersecurity software vendor said Nir Zuk, who founded the company in 2005, is retiring from his role as chief technology officer.

The stock rose about 6% in extended trading.

Here’s how the company did compared to LSEG estimates:

  • Earnings: 95 cents adjusted vs. 88 cents expected
  • Revenue: $2.54 billion vs. $2.5 billion expected.

Revenue in the fiscal fourth quarter rose 16% from about $2.2 billion last year, the company said in a statement. Net income fell to about $254 million, or 36 cents per share, from about $358 million, or 51 cents per share, in the year-ago period.

The company also issued upbeat guidance for the fiscal first quarter. Earnings per share will be between 88 cents and 90 cents, Palo Alto said, topping an 85-cents estimate from StreetAccount.

For the full year, Palo Alto said revenue will range from $10.48 billion to $10.53 billion on adjusted earnings of $3.75 to $3.85 per share. Both estimates exceeded Wall Street’s projections.

Palo Alto said that for the fiscal first quarter, remaining purchase obligations, which tracks backlog, will range between $15.4 billion and $15.5 billion, surpassing a $15.07 billion estimate.

Last month, the company announced plans to buy Israeli identity security provider CyberArk for $25 billion. It’s the largest deal Palo Alto has made since its founding, and most ambitious in an acquiring spree that ramped up after CEO Nikesh Arora took the helm of the company in 2018.

Shares sold off sharply after the news broke and have yet to recover previous highs. The stock is down about 3% this year as of Monday’s close.

“We look for great products, a team that can execute in the product, and we let them run it,” Arora told CNBC following the announcement. “This is going to be a different challenge, but we’ve done well 24 times, so I’m pretty confident that our team can handle this.”

Lee Klarich, the company’s product chief, will replace Zuk as CTO and fill his position on the board.

WATCH: Power check on Palo Alto, Viking Holdings and Estee Lauder

Power Check: Palo Alto Networks, Viking Holdings, and Estee Lauder

Continue Reading

Politics

US Treasury calls for public comment on GENIUS stablecoin bill

Published

on

By

US Treasury calls for public comment on GENIUS stablecoin bill

US Treasury calls for public comment on GENIUS stablecoin bill

The comments, due by Oct. 17, will focus on “innovative methods to detect illicit activity involving digital assets,” as required by the GENIUS Act.

Continue Reading

Entertainment

‘Ketamine Queen’ to plead guilty to supplying dose of drug that killed Matthew Perry

Published

on

By

'Ketamine Queen' to plead guilty to supplying dose of drug that killed Matthew Perry

A woman who was charged with selling Friends star Matthew Parry the dose of the drug that killed him has agreed to plead guilty.

Jasveen Sangha, known as the “Ketamine Queen”, is the fifth and final defendant to strike a plea deal with prosecutors, avoiding a trial that was set to take place in September.

The 42-year-old agreed to plead guilty to five federal criminal charges, including providing the Ketamine that led to Perry’s death, federal prosecutors said in a statement.

She agreed to plead guilty to five federal criminal charges, including providing the Ketamine that led to Perry’s death, federal prosecutors said in a statement.

Prosecutors had cast Sangha, a dual US and UK national, as a prolific drug dealer known to her customers as the “Ketamine Queen”, often using the term in court documents and even including it in the official name of the case.

Actor Matthew Perry in 2015. File pic: Reuters
Image:
Actor Matthew Perry in 2015. File pic: Reuters


She agreed to plead guilty to one count of maintaining a drug-involved premises, three counts of distribution of ketamine, and one count of distribution of ketamine resulting in death or serious bodily injury.

Sangha will officially change her plea to guilty at an upcoming hearing, where sentencing will be scheduled, prosecutors said.

More from Ents & Arts

Dr. Mark Chavez, a physician from San Diego, who is charged in connection with Matthew Perry's fatal overdose. Pic: AP
Image:
Dr. Mark Chavez, a physician from San Diego, who is charged in connection with Matthew Perry’s fatal overdose. Pic: AP

She is facing up to 45 years in prison.

Sangha and a doctor named Salvador Plasencia, who signed his own plea deal in June, had been the primary targets of the investigation.

Three other defendants – Mark Chavez, who it was claimed bought the drug from Sangha, Kenneth Iwamasa, and Erik Flemin – agreed to plead guilty last year in exchange for their cooperation, which included statements implicating Sangha and Plasencia.

Friends became one of the most popular TV shows in the world in the 1990s and 2000s
Image:
Friends became one of the most popular TV shows in the world in the 1990s and 2000s

Prosecutors allege Chavez funnelled ketamine to Plasencia, securing some of the drug from a wholesale distributor through a fraudulent prescription.

In one instance, prosecutors allege that Plasencia “charged Perry $2,000 (£1,500) a vial that cost Dr Chavez approximately $12 (£9)”.

Perry died in his home in October 2023, aged 54, after getting ketamine from his regular doctor for treatment of depression, which is an increasingly common use for the surgical anaesthetic.

The actor was taking ketamine six to eight times a day before he died, according to court documents.

You can receive breaking news alerts on a smartphone or tablet via the Sky News app. You can also follow us on WhatsApp and subscribe to our YouTube channel to keep up with the latest news.

Continue Reading

Trending